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SUMMARY
ADP-ribosylation refers to the addition of one or more ADP-ribose groups onto proteins. The 
attached ADP-ribose monomers or polymers, commonly known as poly(ADP-ribose) (PAR), 
modulate the activities of the modified substrates or their binding affinities to other proteins. 
However, progress in this area is hindered by a lack of tools to investigate this protein 
modification. Here, we describe a new method named ELTA (Enzymatic Labeling of Terminal 
ADP-ribose) for labeling free or protein-conjugated ADP-ribose monomers and polymers at their 
2’-OH termini using the enzyme OAS1 and dATP. When coupled with various dATP analogs (e.g., 
radioactive, fluorescent, affinity tags), ELTA can be used to explore PAR biology with techniques 
routinely used to investigate DNA/RNA function. We demonstrate that ELTA enables the 
biophysical measurements of protein binding to PAR of a defined length, detection of PAR length 
from proteins and cells, and enrichment of sub-femtomole amounts of ADP-ribosylated peptides 
from cell lysates.
Graphical Abstract
*Corresponding Author and Lead Contact. Correspondence should be addressed to A.K.L.L. (anthony.leung@jhu.edu).
AUTHOR CONTRIBUTIONS
Conceptualization, A.K.L.L.; Methodology, Y.A., E.E., R.L.M., and A.K.L.L.; Investigation, Y.A., E.E., R.L.M., M.D., S-J.C., S-E.O., 
and A.K.L.L.; Resources, J.V., and D.F.; Writing – Original Draft, Y.A., E.E., R.L.M, and A.K.L.L.; Writing – Review & Editing, 
Y.A., E.E., R.L.M., M.D., S-J.C., D.V.F, S-E.O, L.J-T, and A.K.L.L.; Supervision, D.F., S-E.O., L.J-T, and A.K.L.L.; Funding 
Acquisition, R.L.M., S-E.O, L.J-T, and A.K.L.L.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
DECLARATION OF INTERESTS
A patent on the ELTA technique was provisionally filed on April 2nd, 2018.
HHS Public Access
Author manuscript
Mol Cell. Author manuscript; available in PMC 2020 February 21.
Published in final edited form as:














Ando, Elkayam and McPherson et al describe a simple, efficient and versatile platform technology 
called ELTA to label free or protein-conjugated ADP-ribose monomers and polymers with dATP 
analogs (radioactive, fluorescent, biotin, clickable tags, etc). With these functionalized tags, ELTA 
simplifies the measurement, detection and enrichment of various forms of ADP-ribose.
INTRODUCTION
ADP-ribosylation involves the transfer of ADP-ribose from NAD+ onto proteins post-
translationally in unicellular and multicellular organisms (Gupte et al., 2017; Palazzo et al., 
2017). ADP-ribose can be added singly as mono(ADP-ribose) (MAR) or in polymeric form 
as poly(ADP-ribose) (PAR) by ADP-ribosyltransferases, including a family of enzymes 
commonly known as poly(ADP-ribose) polymerases (PARPs) (Cohen and Chang, 2018; 
Hottiger et al., 2010; Lüscher et al., 2018; Palazzo et al., 2017; Pascal and Ellenberger, 
2015). ADP-ribosylation can be reversed by macrodomain-containing enzymes, including 
poly(ADP-ribose) glycohydrolase (PARG) (Barkauskaite et al., 2013; Feijs et al., 2013; 
Pascal and Ellenberger, 2015). The delicate balance of ADP-ribosylation is critical for 
regulating DNA damage repair, transcription, chromatin structure, non-membranous 
structure formation, host-pathogen interactions and RNA metabolism (Bock et al., 2015; 
Hottiger, 2015; Leung, 2014; Lüscher et al., 2018; Zhen and Yu, 2018). Dysregulation of 
ADP-ribosylation or PARP activity has been implicated in the pathogenesis of diseases 
including cancers, virus infection and neurodegeneration (Lüscher et al., 2018; Rouleau et 
al., 2010). Inhibitors of certain PARP family members have already shown promise in 
treating ovarian, prostate, breast and other cancers, with three drugs approved by the FDA 
(Lord and Ashworth, 2017). Additionally, these inhibitors could be repurposed for non-
oncological diseases (Berger et al., 2017). Though this therapeutically important 
modification was discovered in 1963, the progress in understanding its structure, interaction, 
and biology has been hampered by a lack of tools.
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Apart from being a protein modification, PAR is a polynucleotide that is chemically similar 
to DNA or RNA. The measurement, detection and enrichment of DNA/RNA in vitro and 
from cells have been made possible by the rather straightforward modification of these 
nucleic acids with a variety of useful tags (e.g., fluorophores, radioactive or biotin) at either 
terminus using enzymes. The lack of a similar bioconjugation technology for PAR makes it 
difficult to adapt existing molecular biology techniques to investigate this polynucleotide.
DESIGN
ADP-ribose has two ribose moieties: one as part of an adenosine group and a non-adenosine 
ribose that exists in an equilibrium between a closed, dominant form and an open chain 
form, which possesses an aldehyde group at its 1” position (Fig. S1a, green). The 1” position 
is chemically reactive and can be conjugated to either a protein or to another ADP-ribose 
from NAD+ to form PAR. It has previously been shown that this 1” aldehyde group can also 
be used for end-labeling through chemical conjugation to carbonyl-reactive biotin analogs 
with 10–20% efficiency (Fahrer et al., 2007). As such, this 1” aldehyde group is unavailable 
for labeling when ADP-ribose is conjugated to a protein. Here we describe a new method 
named ELTA (Enzymatic Labeling of Terminal ADP-ribose) to label free or protein-
conjugated ADP-ribose monomers and polymers at their 2’-OH termini. We demonstrate 
that ELTA is a sensitive approach to label and assess the length of PAR isolated from 
proteins and cells. When coupled with different chemical analogs, ELTA can be used for 
various applications including fluorescence-based biophysical measurement of PAR-protein 
interaction and enrichment of ADP-ribosylated peptides for mass spectrometry 
identification.
To label ADP-ribose and its derivatives at the 2’-OH terminus (Fig. 1a and S1a, red), we 
used the double-stranded RNA-activated human enzyme 2’−5’-Oligoadenylate Synthetase 1 
(OAS1) (Hornung et al., 2014; Justesen et al., 2000; Kristiansen et al., 2011). OAS1 
oligomerizes ATP into 2’−5’ linked oligoadenylate, where the α-phosphate of the donor 
ATP is linked to the 2’-OH of the acceptor ATP and the resultant AMP moiety with a free 
2’-OH serves as an additional acceptor to facilitate oligomerization (Hornung et al., 2014; 
Justesen et al., 2000; Kristiansen et al., 2011). Two pieces of data suggested that OAS1 
would have the potential to be used as a labeling tool for ADP-ribose. First, apart from ATP, 
OAS1 can use other derivatives of adenosine with free 2’-OH group as acceptors, including 
NAD+ (Ball and White, 1979; Ferbus et al., 1981) and ADP-ribose (Cayley and Kerr, 1982). 
Second, OAS1 can use other NTPs such as deoxy-ATP (dATP) (Justesen et al., 2000) as 
donors. Because dATP lacks a 2’-OH group and it cannot serve as an OAS1 acceptor for 
further chain extension (Justesen et al., 1980), we reason that it will be useful for end-
labeling. Therefore, if dATP could be added to the 2’-OH terminus of free and protein-
conjugated ADP-ribose monomers or polymers, dATP would be an ideal donor substrate of 
OAS1 to end-label these types of acceptor molecules.
Ando et al. Page 3














The basis of ELTA: Enzymatic addition of dAMP onto 2’-OH termini of ADP-ribose 
monomers and polymers by OAS1
To test whether OAS1 can use dATP as a donor substrate for ADP-ribose in vitro, 
recombinant OAS1 activated by poly(I:C) dsRNA was incubated with ADP-ribose and α
−32P-dATP (hereafter 32P-dATP). In agreement with our premise, a major radioactive 
product running above 32P-dATP was observed (Fig. 1b, S1b). Similarly, OAS1 labels NAD
+, but not the iso-ADP-ribose (the internal unit of PAR which has the same chemical 
composition as ADP-ribose) presumably because the latter lacks an adenosine moiety with a 
free 2’-OH (Fig. S1b). To further confirm the addition of a dAMP moiety onto ADP-ribose 
by OAS1, we used matrix assisted laser desorption ionization-time of flight (MALDI-TOF) 
mass spectrometry analysis to monitor an in vitro labeling experiment of ADP-ribose and 
dATP in 1:1 ratio (Fig. 1c). In the absence of OAS1, dATP and ADP-ribose were observed at 
m/z of 492.0 and 560.0, respectively. In the presence of OAS1, the peaks for ADP-ribose 
and dATP were significantly reduced with an additional peak observed at m/z of 873.0, 
corresponding to the expected [M+H]+ of ADP-ribose–dAMP product.
Given that the internal unit of PAR cannot be labeled (Fig. S1b) but each linear PAR chain 
has one 2’-OH terminus (Fig. S1a), we next investigated whether different lengths of PAR 
can also be end-labeled. Short (≤15-mer), medium (15–40-mer) and long (≥40-mer) PAR 
polymers (Tan et al., 2012) were incubated with OAS1 and 32P-dATP (Fig. 1b). In each case, 
these PAR molecules of different lengths were effectively labeled (Fig. 1b). To test whether 
PAR length affects labeling efficiency, we optimized a purification method (Tan et al., 2012) 
to efficiently separate PAR into defined chain lengths (Fig. S1c). We then used the same 32P-
dATPOAS1 method to label equal amounts of defined PAR length chains (Fig. S1d). As 
expected, PAR chains of different lengths were labeled with comparable efficiency (Fig. 
S1d). Taken together, OAS1 can label both ADP-ribose monomers and polymers using 
radiolabeled dATP.
OAS1 adds dAMP onto protein-conjugated ADP-ribose
As ADP-ribose can be covalently linked to a protein at its 1” terminus (Fig. S1a), we 
reasoned that a protein-conjugated ADP-ribose with a free 2’-OH group could also be served 
as an OAS1 substrate. Using either automodified PARP10 catalytic domain (PARP10CD) 
(Kleine et al., 2008) or Herpetosiphon aurantiacus PARP (haPARP) (Slade et al., 2011) as 
model substrates, respectively, for mono(ADP-ribosyl)ated (MARylated) and poly(ADP-
ribosyl)ated (PARylated) proteins, we tested whether these ADP-ribosylated substrates can 
be labeled by OAS1 with 32P-dATP (Fig. 1d, e). As a negative control, we pre-treated the 
ADP-ribosylated substrates with hsNudT16 (Daniels et al., 2015b; Palazzo et al., 2015), 
which cleaves the pyrophosphate bond within ADP-ribose (cf. Fig. S1a) to leave a 
phosphoribose group on protein residues that were previously ADP-ribosylated. As a result, 
the 2’-OH containing adenosine-linked ribose is removed, and these phosphoribosylated 
proteins are no longer recognized by the Af1521 macrodomain (pan-ADP-ribose reagent; 
Gibson et al., 2017) nor are substrates for OAS1 labeling (Fig. 1d, e). On the other hand, 
MARylated PARP10CD and PARylated haPARP were indeed labeled by 32P-dATP in the 
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presence of OAS1 (Fig. 1d, e). Therefore, this OAS1-based method presents a novel 
approach to label both protein-conjugated ADP-ribose monomers and polymers.
OAS1 is a versatile enzyme that accepts different modified dATP analogs for labeling
Next, we investigated whether the OAS1 enzymatic labeling reaction can be extended to the 
labeling of ADP-ribose with modified dATP analogs. Following a similar labeling protocol, 
we used Cy5-dATP attached at two different positions on the adenine base (N6 and N7; Fig. 
1a and S2a). We efficiently labeled three different PAR chain lengths (10-mer, 15-mer, and 
20-mer) and a mixture of 6–23-mer PAR chains with the two Cy5 analogs (Fig. S2a). PAR is 
completely labeled when Cy5-dATP is used in five-fold excess or more (Fig. S2b–c). OAS1 
labeling can also be performed with other fluorescent derivatives such as Cy3 (Fig. S2d), or 
with biotinylated dATP (Fig. S2e). In addition, this labeling reaction can also be performed 
on protein-conjugated ADP-ribose using modified dATP as well as performed in a range of 
detergent and denaturing conditions (Fig. S1e and S2f–i).
Given the versatility of OAS1 to label free and protein-conjugated ADP-ribose using a range 
of dATP analogs (Fig. 1a), we present this approach as a general method to enzymatically 
label terminal ADP-ribose and named it ELTA (Enzymatic Labeling of Terminal ADP-
ribose). Using several proof-of-concept applications, we illustrate how to use ELTA for 
measurement (Fig. 2), detection (Fig. 3) and enrichment (Fig. 4) while investigating ADP-
ribosylation biology.
Labeled PAR chains can be used to measure the affinity of PAR binding to proteins in vitro
PARylation of target proteins regulates many biological processes (Gupte et al., 2017; 
Hottiger, 2015; Leung, 2014; Lüscher et al., 2018; Palazzo et al., 2017). For example, PAR 
recognition by the WWE domain of RNF146 is required for the poly-ubiquitination and 
subsequent degradation of axin—a key regulator of the Wnt signaling pathway (Zhang et al., 
2011). PAR-binding affinity has been previously assayed using fluorescently labeled di-
ADP-ribose by fluorescent polarization (Lambrecht et al., 2015), or biotinylated PAR by 
electrophoretic mobility shift assay or surface plasmon resonance (Fahrer et al., 2007; 2010). 
However, both methods require PAR synthesis and conjugation through chemical 
approaches to label the PAR, which are not readily accessible to most molecular biology 
laboratories. Alternatively, PAR-binding affinity can be assayed with either a mixed 
population of PAR or with the internal unit iso-ADP-ribose as a proxy (Wang et al., 2012; 
Zhang et al., 2014) using isothermal titration calorimetry (ITC), which requires significant 
amounts of materials (typically at M concentrations). By combining ELTA with our 
improved single-length PAR chain purification (Fig. 2a and Fig. S1c), we were able to 
measure the affinity of a single-length PAR chain to the WWE domain of RNF146. First, we 
used a filter-binding assay and measured the affinity of radiolabeled 10- and 20-mer PAR to 
the RNF146 WWE domain (Fig. 2b). Both PAR chains bind tightly to the RNF146 WWE 
domain with binding constants of 75±2.5 nM (10-mer) and 67±2.3nM (20-mer). We further 
extended our repertoire of biophysical measurements of the PAR binding assays by using the 
commonly used Cy5 fluorescence dye and measured the affinity of Cy5-PAR to the RNF146 
WWE domain (100±9nM; Fig. 2c) using Microscale Thermophoresis (MST) (Wienken et 
al., 2010). Binding constants from both methods are similar considering the use of different 
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methodologies. However, when compared to the affinity reported for RNF146 WWE domain 
binding to iso-ADP-ribose that was used by Wang et al. 2012 and Zhang et al., 2014, a small 
but noticeable difference was observed (67–100nM compared to 180–370nM; Wang et al., 
2012; Zhang et al., 2014). These differences could be readily explained by the different sizes 
of the ligands used—the full polymer vs. the internal unit iso-ADP-ribose as a proxy—
where a longer PAR chain that harbors a high net negative charge would be expected to bind 
with higher affinity. Indeed, the binding constant obtained using ITC of another PAR 
binding protein, hSSB1, titrated with a mixture of 10–25-mer PAR (Kd=150nM, Zhang et 
al., 2014) yielded a similar binding constant to those observed in our study.
Detection of polymer length of PAR isolated from individual proteins and cells
The number of ADP-ribose units attached to proteins is dynamically regulated within cells 
and, notably, protein binding to PAR is dependent on its chain length in some cases (Fahrer 
et al., 2007; Leung, 2014; Min et al., 2013; Popp et al., 2013). Though it is possible to 
visualize the length of PAR polymers using SYBR Gold or silver stain (Malanga et al., 
1995), such methods cannot be used to visualize very short polymers (Fig. S1d and S3a). 
Alternatively, it is possible to infer the length of PAR from ADP-ribosylated proteins only if 
they are modified with radioactive NAD+ in vitro. Given that ELTA can effectively add a 
single label to each 2’-OH terminus of pre-made PAR, we tested whether this labeling 
technique can be used to determine the chain length of PAR isolated from proteins already 
ADP-ribosylated and compare with the existing technique that requires radioactive NAD+ 
incorporation. To examine the labeling efficiency of PAR isolated from PARylated PARP1, 
we performed automodification of PARP1 with 1 mM NAD+ with or without a trace of 32P-
NAD+ for either 0, 10, or 30 min (Fig. 3a). The non-radioactive protein samples were, on the 
other hand, labeled by OAS1 with 32P-dATP (no unlabeled dATP). PAR was then extracted 
from both 32P-NAD+ and 32P-dATP labeled samples and visualized by autoradiography. 
PAR isolated from ADP-ribosylated proteins can be efficiently labeled and the patterns of 
isolated PAR samples labeled by 32P-NAD+ and 32P-dATP are comparable in length 
distribution (Fig. 3a). We note that the commercially available 32P-NAD+ is limited at ~7 
μM, which is insufficient for most in vitro modification without the addition of unlabeled 
NAD+ and thereby constitutes only a small fraction of ADP-ribose incorporated (<0.003% 
in this case). In contrast, the 32P-dATP signal directly reflects the number of 2’-OH termini 
of PAR labeled by OAS1. To further illustrate the potential of the use of ELTA in assessing 
PAR length of ADP-ribosylated proteins/complexes, we modified PARP1 with NAD+ in the 
absence or presence of its interacting protein HPF1. HPF1 binding alters PARP1 substrate 
specificity by reducing auto-modification of PARP1 as observed by the altered molecular 
weight of PARP1 on western blot (Fig. S3b; Gibbs-Seymour et al., 2016). To test whether 
such change in molecular weight of PARP1 is due to altered polymer length, we subjected 
the reaction mixture for ELTA labeling. Indeed, the addition of HPF1 reduced both the 
amount and length of PAR associated with PARP1 (Fig. 3b). Taken together, ELTA provides 
a sensitive approach to assess the polymer length of ADP-ribosylated proteins or complexes 
in their native modified state.
Next, we tested whether ELTA can be used to detect the length of PAR isolated from cells 
(Fig. 3c). PAR was isolated from cells using a solid-phase extraction method that allows for 
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the high recovery of PAR without any bias for different chain lengths (Martello et al., 2013). 
Human keratinocyte HaCaT cells were either untreated or H2O2-treated to induce 
PARylation, pre-treated with the PARP inhibitor Olaparib prior to H2O2, or pre-treated with 
PARG inhibitor PDD 00017273 (James et al., 2016) prior to H2O2. As a control, we also 
isolated PAR from in vitro modified haPARP, which generates PAR of 2–25mer in length 
(Slade et al., 2011). As expected, we observed significant PAR signals in H2O2-treated cell 
samples (Fig. 3c; lane 3), which is longer than the one isolated from haPARP (lane 1). PARP 
inhibitor Olaparib (lane 4) reduced the signal to background levels similar to the untreated 
cells (lane 2). On the contrary, PARG inhibition resulted in the enrichment of overall signals, 
confirming that the observed signals are indeed PAR (lane 5). Taking advantage of this novel 
approach to assess PAR length in cells, we labeled PAR isolated from 0, 2.5, 5, 7.5, and 10 
min of H2O2-treatment and observed a distinctive shift in the profile of the polymer length 
over the time-course (Fig. S3c). Taken together, ELTA can be used to assess the length of 
PAR isolated from individual proteins or cells.
ELTA allows for selective labeling and enrichment of ADP-ribosylated peptides
Building on our findings that ELTA can be used to label protein-conjugated ADP-ribose (cf. 
Fig. 1d, e), we sought to develop a workflow for selective labeling and enrichment of ADP-
ribosylated peptides from cell lysates, which may be applied to existing global ADP-
ribosylated proteome analyses (Carter-O’Connell et al., 2014; Daniels et al., 2015a; Gibson 
et al., 2016; Larsen et al., 2018; Leidecker et al., 2016; Pedrioli et al., 2018; Martello et al., 
2016; Westcott et al., 2017; Zhang et al., 2013; Zhen et al., 2017). We propose a pipeline 
composed of three steps that are illustrated in Fig. 4a: (1) the labeling of ADP-ribosylated 
peptides with the “clickable” dATP analog, N6-(N-azido)hexyl-dATP, by OAS1, (2) 
conjugation of OAS1-labeled peptides to dibenzocyclooctyne (DBCO)-agarose through 
copper-free click chemistry (Jewett and Bertozzi, 2010), and (3) treatment of agarose-
conjugated peptides with hsNudT16 phosphodiesterase to release peptides, now possessing a 
phosphoribose tag at former sites of ADP-ribosylation, for mass spectrometry analysis 
(Daniels et al., 2015b).
First, we tested whether OAS1 can label a glutamine ADP-ribosylated peptide, HK533 
(Kistemaker et al., 2016), with N6-(N-azido)hexyl-dATP and analyzed the reaction product 
by MALDI-TOF. As expected, a peak shift of 438.1 Da was observed (Fig. 4b, panel 1), 
which corresponds to N6-(N-azido)hexyl-dAMP. Next, we incubated this reaction with 
DBCO-agarose to allow for the conjugation of N6-(N-azido)hexyl-dAMP-labeled HK533 to 
the resin. We observed that there were no peaks in the mass range of N6-(N-azido)hexyl-
dAMP-labeled HK533 in the flowthrough (Fig. 4b, red profile in panel 2), suggesting that a 
large proportion of the N6-(N-azido)hexyl-dAMP-labeled HK533 was conjugated to and 
pulled down by the DBCO-agarose. Consistently, the unlabeled HK533 peptide was present 
in the flowthrough of the sample not treated with OAS1 (Fig. 4b, black profile in panel 2), 
but absent in the sample treated with OAS1 (red profile). These data indicate that unlabeled 
HK533 is not significantly retained by the DBCO-agarose. To confirm the conjugation of 
N6-(N-azido)hexyl-dAMP-labeled HK533 peptide with the resin, we treated the peptide-
conjugated DBCO-agarose resin with hsNudT16 (cf. Fig. 1d, e; Fig. 4a). We observed the 
largest peak (1529.9 m/z) at the expected m/z (1529.8) for phosphoribosylated HK533 in the 
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eluent of the peptide sample treated with OAS1 (Fig. 4b, red profile in panel 3) and no 
significant peaks in the sample without OAS1 (black profile). To test whether ELTA labeling 
is affected by the type of amino acid conjugated with ADP-ribose, we also tested a serine 
ADP-ribosylated peptide, JV-099 (Voorneveld et al., 2018; Fig. S4a, b). Similar efficiency in 
labeling and enrichment was observed, suggesting that the ELTA method can label peptide 
irrespective of the nature of the conjugated site or its neighboring residues.
Next, we assessed whether our workflow could be applied to enrich ADP-ribosylated 
peptides from lysates and identify the modification sites by liquid chromatography tandem 
mass spectrometry (LC-MS/MS). We added 1 nmol of HK533 into 1 mg of a tryptic digest 
of HeLa cell lysates (~1 μmol total peptides) and used this complex peptide mixture as the 
input for ELTA-based enrichment workflow. LC-MS/MS analyses of the input and eluent 
demonstrated that the workflow resulted in the robust enrichment of molecular species with 
a retention time of ~6.5 min (Fig. 4c, panels 1 and 2). MS analysis of this peak demonstrated 
that it was predominantly composed of two species that matched the expected m/z for 
phosphoribosylated HK533 in the +2 and +3 charge states (Fig. 4c, panel 3). Subsequent 
MS/MS analyses confirmed the sequence and ADP-ribosylated site localization of HK533 
(Fig. S4c). To test the sensitivity of our approach, we repeated the experiment by mixing 1 
pmol or 1 fmol of HK533 into ~1 μmol total peptides, where 50% of the samples were 
subjected for MS analyses. In each case, HK533 was identified (Fig. 4d), suggesting that our 
pipeline can identify ADP-ribosylated peptides with sub-femtomole sensitivity.
As an initial attempt to explore whether the current pipeline can also be used to enrich 
endogenous ADP-ribosylated peptides, we performed the ELTA-based enrichment workflow 
in triplicate using 2.5 mg of tryptic digest of H2O2-treated HeLa cell lysates as the input. As 
above, we labeled tryptic peptides with N6-(N-azido)hexyl-dATP by ELTA, conjugated the 
labeled peptide to DBCO-agarose, and eluted with hsNudT16 that resulted in 
phosphoribosylated peptides for LC-MS/MS analyses. We identified 175 endogenous ADP-
ribosylated peptides and 123 proteins in total (Table S1; Methods S1). Among the 123 
proteins, 95 of them identified in previous studies based on cross-comparison with 
ADPriboDB (Vivelo et al., 2016). A statistically significant overlap was observed at a p-
value of 7.3 × 10−98 using Fisher’s exact test. Amongst them, 29 proteins were identified in 
two or more replicates, with ~90% overlap with ADPriboDB (26 proteins, p = 6.3 × 10−31; 
Table S1). This significant overlap corresponds to 35 out of 41 endogenous ADP-ribosylated 
peptides which are modified at a range of amino acids (e.g., Fig. 4e, see also Table S1 and 
Methods S1). Therefore, ELTA is capable of enriching for endogenous ADP-ribosylated 
peptides, which feature a variety of sequences on the peptide backbone and modified sites.
DISCUSSION
ELTA: an efficient, straightforward and versatile method to label free and protein-
conjugated ADP-ribose
We report a novel enzymatic approach to label the 2’-OH terminus of ADP-ribose 
monomers and polymers. Though it has been possible to label ADP-ribose at its 1” aldehyde 
using a chemical approach (Fahrer et al., 2007), ELTA is an easy, efficient and 
straightforward method that could be used in conventional molecular biology labs without 
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special equipment or expertise. In addition, ELTA has now made it possible to label ADP-
ribose that is also conjugated to a protein at the 1” position (cf. Fig. S1a). Since OAS1 
accepts a range of commercially available dATP analogs as substrates, ELTA is a flexible 
tool that can incorporate standard molecular biology techniques that require the 
derivatization of the assayed molecule (e.g., radioactive, fluorescent, etc.) to study PAR. We 
have demonstrated several proof-of-concept applications: (1) the use of fluorescently labeled 
PAR of defined chain length for biophysical measurements; (2) radiolabeling of PAR 
isolated from cells or individual proteins to allow the detection of their associated polymer 
length; (3) the use of an azide tag to directly conjugate ADP-ribosylated peptides onto 
agarose beads by click chemistry for the downstream enrichment of ADP-ribosylated 
substrates and mass spectrometry identification. The possibility of covalently linking ADP-
ribose or ADP-ribosylated protein to solid supports opens avenues for nanoparticle delivery 
or solid-phase chemistry. We noted that azido labeling also allows us to tap into the 
versatility of click chemistry for bioconjugation to any compatible substrates. Given that the 
synthetic routes for preparing various ATP derivatives are established (Bagshaw, 2001), it is 
foreseeable that similar dATP analogs can be made and applied to ELTA for new 
applications. For example, adding fluorine-19 for making an NMR probe or a diazirine 
group for a photo-affinity probe (Bagshaw, 2001).
ELTA is distinct from other reagents, such as antibodies or protein domains, that recognize 
ADP-ribose (Affar et al., 1999; Gibson et al., 2017; Kawamitsu et al., 1984) in that it goes 
beyond functioning as a detection reagent. ELTA allows researchers to modify ADP-ribose 
with a variety of labels that allows for further measurement, enrichment as well as detection. 
While antibodies are developed against PAR of specific ADP-ribose length (Affar et al., 
1999; Kawamitsu et al., 1984) and protein domains may have sequence specificities beyond 
the protein-conjugated ADP-ribose (Forst et al., 2013; Moyle and Muir, 2010), ELTA targets 
a chemical group that is present in various forms of ADP-ribose (i.e., 2’-OH terminus), 
which allows quantitative comparisons between different forms based on detection of a 
consistent tag (e.g., biotin).
ELTA simplifies the measurement, detection and enrichment of ADP-ribosylation
Currently, ELTA can be used to effectively label sub-femtomole levels of ADP-ribose, 
thereby allowing for efficient labeling of limited materials for downstream analyses. We 
have demonstrated the use of radioactive and fluorescent PAR of defined length for 
measurement of the equilibrium dissociation constant with a PAR-binding module using 
filter binding assays and MST, respectively. We note that only trace amounts of labeled PAR 
polymers are required compared to the current methods that require large quantities of PAR 
polymers that are often outside the reach of most academic laboratories. These labeled 
molecules can also be used for single molecule-based measurement (Chen and Larson, 
2016) or intracellular tracking of PAR (Krukenberg et al., 2015). When combined with the 
existing chemical approach to label PAR at 1” position, ELTA can be used to attach 
functionalities at both termini. Such a dual labeling approach has been transformative for 
studying DNA and RNA biology, and, therefore, ELTA may now open the possibility for 
PAR to serve as a building block in synthetic biology, such as creating model ADP-
ribosylated proteins with a defined PAR length. Given that ELTA labels the 2’-OH terminus 
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and that some PARPs create branched points resulting in additional 2’-OH groups from a 
single 1” terminus, labeling at both 1” and 2’ ends may help in determining the branching 
frequency of intact PAR polymers isolated from individual proteins or cells.
Several methods have been developed to measure the length of PAR chain from cells; 
however, the majority of them require the digestion of PAR into monomeric nucleosides 
prior to analyses (Juarez-Salinas et al., 1979; Kanai et al., 1982; Keith et al., 1990; Martello 
et al., 2013; Shah et al., 1995), thereby losing the information of length distribution of intact 
PAR chains. Alternatively, it is possible to measure the length of intact PAR chains from 
cells by feeding them with radiolabeled adenine (Aboul-Ela et al., 1988; Alvarez-Gonzalez 
and Jacobson, 1987). However, this approach suffers from several drawbacks, including non-
specific labeling of other polynucleotides (DNA and RNA) and potential induction of PAR 
signals by the radiodamage of DNA (Martello et al., 2013). Nucleic acid staining such as 
silver stain and SYBR Gold are, on the other hand, insensitive to very short chains (cf. Fig. 
S1d and S3a); as their signals are approximately correlated to the number of the ADP-ribose 
groups present in the PAR chain, these methods may not be useful for quantifying the 
differences between PAR of different chain lengths. Using ELTA, a single radioactive label 
is added to the end of a 2’-OH terminus and, therefore, the signal observed is directly 
correlated to the number of 2’-OH termini of PAR of any given individual length. Though 
multiple 2’-OH termini may be present due to PAR branching, the quantitation of different 
chain lengths will likely be minimally affected as branching occurs at a level of 1–2% 
(Martello et al., 2013). As PARP inhibitors are currently used to treat cancer patients and in 
clinical trials for other diseases, ELTA can help evaluate the effect of these drugs on cellular 
ADP-ribosylation comprehensively—i.e., by monitoring changes of both site and length of 
ADP-ribosylation. We found that PAR length distribution reduced significantly by PARP 
inhibitors and PAR accumulated with an altered profile upon PARG inhibition. Whether the 
latter profile change is related to the differential processivity of PARG activity observed for 
different PAR length in vitro (Brochu et al., 1994) warrants further investigation. Notably, 
FDA-approved PARP inhibitors, including Niraparib and Olaparib, have clinical efficacy and 
accumulate DNA damage only when the PAR level is reduced by >90% (Moulder and 
Hedley, 2016). One possible interpretation is that a longer PAR chain can still result in DNA 
repair, but not a shorter one, consistent with previous observations that DNA repair factors 
bind to PAR in a length-selective manner (Fahrer et al., 2007; Leung, 2014; Min et al., 2013; 
Popp et al., 2013). Therefore, it will be interesting to explore whether PAR length 
distribution could be an important biomarker for the clinical effectiveness of these inhibitors.
Beyond free and protein-conjugated ADP-ribose
In summary, we demonstrated that ELTA can be used to label free and protein-conjugated 
ADP-ribose and provided examples of its applications. However, this novel technique may 
have broader applications for ADP-ribose metabolism. Besides protein-conjugated ADP-
ribose, studies in prokaryotes and eukaryotes have revealed several ADP-ribose derivatives 
that have free 2’-OH groups, including O-acetyl-ADP-ribose generated by the sirtuin 
deacetylase family, ADP-ribose-1”-phosphate from tRNA splicing, ADP-ribosylation of the 
antibiotics rifamycin, as well as the recently discovered DNA ADP-ribosylation (reviewed in 
Palazzo et al., 2017). ELTA may, therefore, provide a timely tool for discovering the 
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functions of these various forms of ADP-ribosylation in antibiotic resistance, as well as 
NAD+, RNA, and DNA metabolism.
LIMITATIONS
We have developed a robust method to label protein-conjugated and free ADP-ribose 
enzymatically. As in any labeling methods, the label itself, however, may affect the binding 
of protein partners. Therefore, any measurement with the labeled molecules should be 
verified independently with existing methods (cf. Fig. 2). Even though ELTA can be used to 
label sub-femtomole of ADP-ribose, the detection is limited by the choice of the label 
attached (e.g., fluorescent or radioactive) and the sensitivity of the detector available. If 
weak signals need to be amplified for detection, ATP can potentially be used in place of 
dATP to form oligomers on ADP-ribose (Cayley and Kerr, 1982). However, this approach 
will be at the expense of the linear response of ELTA, which exhibits a 1:1 relationship 
between observed signals and 2’-OH terminus present in ADP-ribose.
STAR★Methods
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact Anthony K. L. Leung (anthony.leung@jhu.edu).
Protein expression and purification
Human OAS1—Full length human 2’−5’-oligoadenylate synthase 1 (OAS1, UniProtKB 
P00973) codon optimized for insect cell expression into the MultiBac pFl vector (Bieniossek 
et al., 2008) with Strep-Sumo tag followed by TEV cleavage site. SF9 cells were infected 
with baculovirus expressing OAS1 for 72 h. The protein was purified using StrepTactin resin 
(IBA bioTAGnology) followed by Strep-Sumo tag removal using TEV protease. The protein 
was further purified by gel filtration using a HiLoad 16/60 superdex 200 column. The 
protein was flash frozen in a buffer containing 50 mM Tris pH 8.0, 100 mM NaCl, 5 mM 
DTT and 10% glycerol, and stored at −80°C until use.
Automodified PARPs—Recombinant PARP1, PARP10CD, hsNudT16, haPARP proteins 
were purified as described previously (Daniels et al., 2015b; McPherson et al., 2017; Slade 
et al., 2011). The automodification of PARPs was performed as described (Daniels et al., 
2014; McPherson et al., 2017). Briefly, PARylated PARP1 proteins were prepared in a 
reaction buffer containing 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 5 mM MgCl2,10 mM β-
mercaptoethanol, 1 mM NAD+ and 2 μM 1x activated DNA (Trevigen) with or without 3 
μCi 32P-NAD+. The mixtures were incubated at 30°C for 30 min and 20 μM Olaparib added 
to stop the reaction. MARylated PARP10CD proteins were prepared in a reaction buffer 
containing 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 5 mM MgCl2, 10 mM β-mercaptoethanol 
and 1 mM NAD+. The mixtures were incubated at 37°C for 2 h. Excess NAD+ was removed 
by desalting in a Zeba Spin Desalting Columns (Thermo Fisher Scientific) equilibrated with 
the reaction buffer. PARylated haPARP proteins were prepared in a reaction containing 18 
μM haPARP, 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 1x activated DNA and 3.5 mM NAD+. 
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The mixture was incubated at 25°C, 500 rpm for 1 h. Excess NAD+ was removed by 
desalting into 50 mM Tris pH 7.5, 50 mM NaCl with a HiTrap desalting column (GE 
healthcare) on an NGC 100 medium-pressure chromatography system (Bio-Rad).
RNF146 WWE domain—The WWE domain of human RNF146 was cloned into pET28a 
vector with His-Sumo tag followed by TEV protease cleavage site. The protein was 
expressed at 18°C for 16 h. The protein was initially purified using NiNTA resin (Qiagen) 
followed by His-Sumo removal with TEV protease. The protein was further purified on SP 
HP cation exchange column (GE healthcare) followed by HiLoad 16/60 superdex 75 size 
exclusion column (GE healthcare). The protein was flash frozen in a buffer containing 50 
mM Tris pH 8.0, 100 mM NaCl, 5 mM DTT and 10% glycerol and stored at −80°C until 
use.
HPLC fractionation of PAR
PAR was synthesized as previously described (Tan et al., 2012). For the fractionation of 
PAR, a semi-preparative DNAPac PA100 column (9 × 250 mm) was used to fractionate PAR 
into homogeneous polymers. Approximately 2.74 μmol (~3 mg) of PAR was loaded onto the 
column equilibrated with Dionex buffer A (25 mM Tris-HCl pH 9.0), and the concentration 
of Dionex buffer B (25 mM Tris-HCl pH 9.0 and 1M NaCl) in a 120-min method was set to 
elute as follows: 0 min (0% B), 6 min (0% B), 10 min (30% B), 60 min (40% B), 78 min 
(50% B), 108 min (56% B), 112 min (100% B), 114 min (100% B), 115 min (0% B), 120 
min (0 % B). The 2-ml fractions were collected and concentrated using Amicon Ultra 
centrifugal filters (Sigma Aldrich).
Labeling of free ADP-ribose with dATP analogs using OAS1
For radiolabeling, ADP-ribose, NAD+, iso-ADP-ribose (10 μM each), or PAR (25 μM each) 
were reacted with 5 μCi α−32P-dATP (Perkin-Elmer), 50 μg/mL low molecular weight 
(LMW) poly(I:C) (Invivogen). Addition of poly(I:C) (synthetic dsRNA analog) is critical as 
it activates OAS1 (Lohöfener et al., 2015). The labeling reaction started by adding 50 μg/mL 
OAS1 in 1x labeling buffer (20 mM Tris-HCl pH 7.5, 20 mM Magnesium Acetate, 2.5 mM 
DTT) at 37°C for 2 h. The samples were resolved on 7 M urea 15% polyacrylamide gel 
followed by autoradiography. For labeling with Cy3-dATP, 10 μM ADP-ribose or PAR were 
incubated with 4 μM Cy3-dATP (Perkin Elmer), 50 μg/mL LMW poly(I:C) and 50 μg/mL 
OAS1 in 1x labeling buffer at 37°C for 2 h. The samples were separated on 7 M urea 15% 
polyacrylamide gel and visualized using a Typhoon FLA7000 machine (GE HealthCare). 
For biotin labeling, 10 μM PAR was incubated with 40 μM biotin-14-dATP (ThermoFisher 
Scientific), 50 μg/mL LMW poly(I:C), 50 μg/mL OAS1 in 1x labeling buffer. The samples 
were applied to Illustra MicroSpin G-25 columns (GE HealthCare) to remove free biotin-14-
dATP and detected by IR dye 800CW Streptavidin (Li-Cor Biosciences) and anti-PAR 
polyclonal antibodies (Trevigen) using dot blot.
Single-length PAR radiolabeling with α−32P-dATP was performed in a reaction consisting 
of 20 mM Tris pH 7.5, 20 mM Magnesium Acetate, 2.5 mM DTT, 0.6 M purified OAS1, 0.5 
mg/ml LMW poly (I:C), 0.05 M PAR, and 0.33 M of dATP, [α−32P]- 3000Ci/mmol. The 
reaction was incubated for 2 h at 37°C, and then the excess of radiolabeld dATP was 
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removed using Illustra MicroSpin G-25 columns. Single-length PAR labeling with Cy5 was 
performed under the same conditions but with 1 M PAR and 10 M of either N6-(6-
Amino)hexyl-dATP -Cy5 (Jena BioSciences) or 10 M of Cy5-dATP (PerkinElmer). For 
Cy5-dATP calibration curve, 1:2 serial dilutions of Cy5-dATP (Perkin-Elmer) were 
measured and fluorescence was plotted using Prism 6 (GraphPad). Cy5-PAR fluorescence 
was then measured, and PAR concentration was calculated using the linear curve equation of 
the Cy5-dATP calibration curve (Fnorm = 2077*[nM] −131.6). To remove poly(I:C) for 
purified PAR, KCl was added to the labeled PAR to a final concentration of 100 mM and 
poly(I:C) was removed by RNase R digestion at 37°C for 1 h. Labeled PAR was then ext 
racted using Trizol-LS reagent (ThermoFisher Scientific) or RiboZol RNA extraction kit 
(VWR).
Labeling of ADP-ribosylated proteins with dATP analogs using OAS1
1 μg automodified proteins (without 32P-NAD+) or the negative control BSA was labeled 
with 4 μCi 32P-dATP, 4 μM Cy3-dATP or 40 μM biotin-14-dATP by 50 μg/mL OAS1 at 
37°C for 2 h. For demodification, automodified proteins were treated with hsNudT16 
proteins at 37°C for 1 h and then labeled with dATP analogs. The protein samples were 
separated on SDS-PAGE. Total protein levels were analyzed with SimplyBlue Safe Stain 
(Thermo Fisher Scientific).
Isolation of 32P-labeled PAR from PARP1 proteins
1 μg automodified PARP1 proteins (without 32P-NAD+) was precipitated with TCA and 
labeled with 4 μCi 32P-dATP by incubation with 50 μg/mL OAS1 at 37°C for 2 h. PAR 
chains were isolated from the 32P-NAD+ labeled PARP1 or 32P-dAMP labeled PARP1 
proteins by shaking with PAR release buffer (1 M KOH and 50 mM EDTA) at 60°C for 2 h. 
PAR solutions were neutralized with HCl to pH 7.5 followed by phenol-chloroform 
purification and ethanol precipitation. The pellets were dissolved in water, and the samples 
were purified with Illustra MicroSpin G-25 columns.
ELTA Labeling of PAR isolated from individual proteins and cells
For PAR isolated from in vitro modified haPARP, 100 μg of haPARP was incubated with 5 
mM NAD+ and 1x activated DNA for 2 h at 30°C in automodification buffer (50 mM Tris-
HCl pH 7.5, 50 mM NaCl). Modified protein was precipitated by 20% (w/v) cold TCA and 
stayed on ice for 15 min. Pellet was centrifuged at 14000xg for 15 min, washed with 70% 
ethanol, and air-dried. For PAR isolated from cells, 1.0 × 106 HaCaT cells were seeded in 10 
cm dishes. When 90% of cell confluence was reached, cells were either treated with or 
without 1 mM H2O2 for 10 min. In addition, 20 μM PARP inhibitor Olaparib or 1 μM PARG 
inhibitor PDD 00017273 were added in DMEM containing 10% FBS for 2 h, then treated 
with 1 mM H2O2 for 10 min. For the time-course experiment, 1.0 × 106 HaCaT cells were 
seeded in 10 cm dish. When 90% of cell confluence was reached, cells were treated with 1 
mM H2O2 for 0, 2.5, 5, 7.5, and 10 minutes. In all cases, cells were washed by ice-cold 1x 
PBS, and cellular proteins were precipitated by 20% (w/v) cold TCA and stayed on ice for 
15 min. Pellets were centrifuged at 3000×g for 10 min, washed by 70% ethanol, and air-
dried. PAR isolated from in vitro modified proteins or from cells was then extracted by 0.5 
M KOH digestion at 37°C for 90 min and neutralized by 0.8 M MOPS buffer. To digest 
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nucleic acids and proteins, samples were treated with 0.08 mg/mL DNase and 0.08 mg/mL 
RNase A for 3 h at 37°C, followed by incubated with 0.16 mg/mL Proteinase K overnight. 
Samples were then purified by High Pure miRNA Isolation Kit (Roche) to enrich samples 
for PAR as previously described (Martello et al., 2013). 100 μl of Milli-Q water was used for 
sample elution.
For characterizing PAR isolated from PARP1 automodification with and without HPF1, 
recombinant PARP1 and HPF1 proteins were purified as previously described (Langelier et 
al 2011, Gibbs-Seymour et al 2015). In a 0.25 mL reaction, PARP1 (10 μM) with HPF1 (10 
μM) or BSA (10 μM) were prepared in a reaction buffer containing 20 mM Tris-HCl pH 7.5, 
50 mM NaCl, 5 mM MgCl, 10 mM β-mercaptoethanol, 1 mM NAD+ 2 and 10 μM duplex 
DNA. The mixtures were incubated at 25°C for 20 min and an equal volume of ice-cold 20% 
TCA was used to stop the reaction. The samples were put on ice for 15 minutes. Proteins 
were precipitated by spinning at 9,000 xg, 4 °C for 10 minutes. Precipitated proteins were 
washed once with ice-cold 70°C e thanol then air-dried. Pellets were resuspended in 255 μL 
0.5 M KOH and incubated at 37°C for 10 minutes. Aft er neutralization with 50 μL 4.8 M 
MOPS buffer, MgCl2 (5 mM) and DNase I (0.1 mg/mL) were added and the samples were 
incubated at 37 °C for 2 hours. CaCl2 (1 mM) and proteinase K (0.2 mg/mL) were added 
and the samples were incubated at 37 °C overnight. PAR isolation was performed with the 
High Pure miRNA isolation kit (Roche) and was eluted with 50 μL Milli-Q water. PAR 
isolated from PARP-1 (5 μL, diluted 1:15 in mQ water) or from PARP-1 + HPF1 (5 μL) was 
labeled with [α−32P]-dATP (4 μCi) and dATP (50 μM) as above. Samples were incubated in 
denaturing PAGE buffer at 70 °C for 10 minutes, then separated on a 15% denaturing 
polyacrylamide gel.
Silver Staining
PAR samples were resolved on 7M urea 15% polyacrylamide gels. After electrophoresis, the 
gel was fixed overnight in 50% ethanol and 5% acetic acid, following by a 30 min wash by 
Milli-Q water for 4 times the next day. The stain was performed by using Pierce™ Color 
Silver Stain Kit (ThermoFisher Scientific). In brief, silver reagent was applied for 30 min, 
following by a short rinse of water for 10 s. An equal amount of reducer base reagent and 
reducer aldehyde reagent was then mixed and applied to the gel for 3–5 min. The gel was 
washed with Milli-Q water to reduce the background, and stabilizer reagent was added for 
another 30 min.
Filter binding Assays
Defined length 32P-labeled PAR chain (200 pM) was incubated with 2-fold serial dilutions 
(20 μM to 0.6 nM) of RNF146 WWE domain. Samples were applied to a slot blot apparatus 
as described (Elkayam et al., 2017). The protein–PAR complex was captured on a 
nitrocellulose membrane, and the free PAR was captured on a subsequent nylon membrane. 
The protein-bound and unbound radiolabeled PAR were visualized by phosphorimaging 
(Typhoon 7000, GE Healthcare) and quantified using GeneTools software (Synoptics). The 
results of three experiments were analyzed using Prism 6 software (GraphPad). Data are 
shown as means of bound PAR/(bound PAR+unbound PAR) ± standard deviation (SD).
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Defined length Cy5-labeled PAR chain (500 pM) was incubated with 2-fold serial dilutions 
(20 μM to 0.6 nM) of RNF146 WWE domain. Binding was measured using Monolith NT.
115 pico (NanoTemper) at 20% excitation power and 40% MST power. Data are shown as 
means of Normalized fluorescence ± SD.
MALDI-TOF analyses
For MALDI-TOF analysis of OAS1-labeled ADP-ribose, 1 mM ADP-ribose was incubated 
with 1 mM dATP (Sigma-Aldich), 20 μg/mL LMW poly(I:C), and 20 μg/mL OAS1 in 1× 
labeling buffer at 37°C for 1 h. After incubation, reactions with ADP-ribose were diluted 1:4 
in a solution containing 80% acetonitrile (ACN; Sigma-Aldrich), 0.1% trifluoroacetic acid 
(TFA; Sigma-Aldrich) and 10 mg/mL 2,5-dihydroxybenzoic acid (DHB; Sigma-Aldrich). 
Samples containing ADP-ribose were analyzed by MALDI-TOF (Applied Biosciences 
Voyager) in reflector, positive-ion mode accelerated at 20 kV with a 65.5% grid and 500 Da 
mass cutoff. HK533 [ac-PQ(ADPr)PAKSAPAPKKG-am] and JV-099 [ac-
PAKS(ADPr)APAPKKG-am] were synthesized as previously described (Kistemaker et al., 
2016; Voorneveld et al., 2018) and resuspended in Milli-Q H2O. For analysis of OAS1-
labeled ADP-ribosylated peptides, ~100 pmol of HK533 or JV-099 in 1 μL was diluted 1:4 
in a solution containing 80% ACN, 0.1% TFA and 10 mg/mL DHB. For analysis of samples 
concentrated on StageTips (Fig. 4b, flowthrough and elution), samples were eluted from 
StageTips with 5 μL of 80% ACN, 0.1% TFA and diluted 1:1 in a solution containing 80% 
ACN, 0.1% TFA and 10 mg/mL DHB. All peptide samples were spotted on a MALDI-TOF 
plate and allowed to dry at room temperature. Samples were analyzed by MALDI-TOF in 
the reflector, positive-ion mode accelerated at 20 kV with a 65.5% grid and 1000 Da mass 
cutoff.
Cell harvesting, proteolysis, and desalting for proteomic analyses
Endogenous ADP-ribosylation was induced in HeLa cells by treatment with 1 mM H2O2 in 
DMEM supplemented with 10% FBS at 37°C for 10 min. HeLa cells were washed once in 
ice-cold 1x PBS and harvested and lysed in 50 mM Tris pH 7.4, 400 mM NaCl, 1 mM 
EDTA, 1% NP-40, 0.1% sodium deoxycholate with 1x SigmaFast protease inhibitor (Sigma-
Aldrich). Insoluble material was cleared by centrifugation and proteins in the soluble 
fraction were precipitated by diluting in a five-fold volume of 100% acetone and stored at 
−20°C overnight. The precipitant was solubilized in 10 mM HEPES pH 8.0, 8 M urea. 
Protein concentration was determined by Bradford assay and adjusted to 5 mg/mL. Proteins 
were then reduced and alkylated with 1 mM TCEP and 6 mM 2-chloroacetamide for 1 h at 
room temperature. The sample was then diluted eight-fold in 25 mM ammonium 
bicarbonate; trypsin (Pierce) and LysC (Wako) were added at a 1:100 enzyme:substrate ratio 
(w/w) and incubated at 37°C overnight. Samples were then acidified to pH 2 with 10% TFA 
and loaded onto a SepPak C18 Classic cartridge conditioned with methanol and equilibrated 
with 0.1% TFA. Immobilized samples were washed with 10 mL 0.1% TFA followed by 30 
mL of Milli-Q H2O and eluted with 3 mL of 80% ACN. Samples were dried by vacuum 
centrifugation to approximately 200 μL and quantified by A280 prior to further use.
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OAS1 labeling, enrichment, and elution of ADP-ribosylated peptide HK533
Specified amounts of HK533 (5 nmol for MALDI-TOF, 1 nmol or less for LC-MS/MS) 
were incubated with 100 μM N6-(6-Azido)hexyl-dATP (Jena Bioscience), 20 μg/mL LMW 
poly(I:C), and 20 μg/mL OAS1 in 1x labeling buffer at 37°C for 1 h. For experiments where 
HK533 was enriched from cell lysate peptides, 1 mg of peptides generated from untreated 
HeLa cells were added to the reaction at a final concentration of 10 mg/mL. For experiments 
enriching for endogenous ADP-ribosylated peptides, 2.5 mg of peptides generated from 
H2O2- treated HeLa cells were added to the reaction at a final concentration of 8.33 mg/mL. 
All OAS1 reactions were then added to 30 μL DBCO-agarose (Click Chemistry Tools) 
equilibrated and resuspended in 300 μL 1x PBS and rotated end-over-end at room 
temperature for 1 h. The samples were briefly centrifuged to pellet the resin, and the 
supernatant (flowthrough) was removed and concentrated on StageTips conditioned with 
80% ACN, 0.1% TFA and equilibrated in 0.1% TFA. StageTips were washed once with 5% 
ACN, 0.1% TFA and stored at 4°C prior to further analysis. By this method, the resin was 
washed thrice with 5M NaCl, and then thrice with 20% ACN containing 0.1% TFA, and 
finally thrice with 1x PBS. The resin was resuspended in 200 μL of 100 mM HEPES pH 8.0, 
15 mM MgCl2. 8 μg of recombinant hsNudT16 was added, and the samples were incubated 
at 37°C for 2 h shaking at 1400 rpm. The samples were briefly centrifuged to pellet the 
resin, and the supernatant was concentrated and desalted on StageTips as described above.
LC-MS/MS analysis
For LC-MS/MS analysis, peptides were eluted from StageTips with 50 μL of 80% ACN and 
0.1% TFA, dried by vacuum centrifugation and resuspended in 10 μL of 5% ACN and 0.1% 
TFA. Peptides were separated on a 75 μm × 150 mm ProntoSIL-120–5-C18 H column (5 
μm, 120 Å, BISHOFF) using a 2–30% ACN gradient in 0.1% acetic acid at 300 nl/min over 
90 min and analyzed on a Thermo Scientific Q Exactive Plus mass spectrometer for analysis 
of HK533 or a Thermo Scientific Fusion Orbitrap for analysis of endogenous ADP-
ribosylated peptides interfaced with an Easy-nLC 1000 (Thermo Fisher Scientific). For 
analysis of HK533 data-dependent analysis was applied using Top15 selection and 
fragmentation was induced by HCD with collision energy set to 28%. Peptides were 
identified from isotopically resolved masses in MS and MS/MS spectra at resolutions of 
70,000 and 35,000, respectively. For analysis of endogenous ADP-ribosylated peptides data-
dependent analysis was applied using Top15 selection and fragmentation of precursors with 
a +2 charge state was induced by HCD with collision energy set to 30% and fragmentation 
of precursors with a +3 charge state or higher was induced by EThCD. Peptides were 
identified from isotopically resolved masses in MS and MS/MS spectra at resolutions of 
120,000 and 30,000, respectively.
Database search of MS/MS spectra for identification of ADP-ribosylated peptide
Raw files were analyzed by MaxQuant version 1.5.7.4 using protein, peptide, and site FDRs 
of 0.01 and a score minimum of 40 for modified peptides and 0 for unmodified peptides and 
delta score minimum of 17 for modified peptides and 0 for unmodified peptides. Sequences 
from HK533 experiments were searched against a FASTA file containing the sequence of 
synthetic ADP-ribosylated peptide HK533. MaxQuant search parameters were set to match 
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the chemical modifications of HK533 and included: variable modifications at acetylation (N-
term), amidation (C-term) and phosphoribosylation (Q). Sequences from endogenous 
peptide experiments were searched against a UniProt FASTA file of the human proteome. 
MaxQuant search parameters were set with variable modifications at acetylation (Protein N-
term), oxidation (M) and phosphoribosylation (DEKRSY) and a fixed modification of 
carbamidomethylation (C). Phosphoribosylation was defined as a modification of C5H9PO7 
(212.009). Max-labeled amino acids were 3, max missed cleavages were 2, enzyme was 
Trypsin/P, max charge was 7, multiplicity was 2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• ELTA labels free or protein-conjugated ADP-ribose monomers and polymers
• ELTA simplifies measurement of protein binding to PAR of a defined chain 
length
• ELTA enables assessment of PAR length from ADP-ribosylated proteins and 
cells
• ELTA allows enrichment of femtomole ADP-ribosylated peptides from 
complex mixtures
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Figure 1. ELTA labels free or protein-conjugated ADP-ribose monomers and polymers.
(a) Schematics of ELTA. Free or protein-conjugated ADP-ribose can be labeled by 
incubating with OAS1 and dATP, where the 2’-OH terminus is indicated in red. Colored box 
indicates various dATP analogs that can also be used in the ELTA reactions, including 
radioactive (32P), fluorescent (Cy3, Cy5), biotinylated or clickable analogs. (b) 15% urea-
PAGE analyses of the addition of 32P-dAMP onto ADP-ribose monomers and polymers 
using ELTA and visualized by autoradiograph. (c) MALDI-TOF analyses of the reaction of 
ADP-ribose with dATP, and with or without OAS1. (d-e) Analyses of the ELTA labeling 
reaction of (d) MARylated PARP10 catalytic domain (mod-PARP10cd) and (e) PARylated 
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haPARP (mod-haPARP) using 32P-dATP. Shown are a coomassie gel (left), an 
autoradiograph (middle), and a western blot probed with pan-ADP-ribose reagent (right). As 
negative controls, modified proteins were treated with the phosphodiesterase hsNudT16 to 
remove the 2’-OH termini of the ADP-ribose groups prior to ELTA labeling. For panel d, * 
indicates PARP10; OAS1 was ADP-ribosylated by PARP10 with the remnant of NAD+, and, 
therefore, detected by pan-ADP-ribose reagent and labeled by OAS1. For panel e, * 
indicates haPARP and § indicates haPARP fragments that were also ADP-ribosylated and, 
therefore, detected by pan-ADP-ribose reagent and labeled by OAS1.
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Figure 2. Biophysical measurement of interaction between PAR-binding protein domain WWE 
and PAR of defined chain length.
(a) Workflow used for ELTA-modified PAR of defined length for biophysical measurement. 
The details of HPLC run are illustrated in Fig. S1c. (b) Filter binding assay of RNF146 
WWE domain binding to 10- and 20-mer PAR, which were radiolabeled using ELTA and 
32P-dATP. (c) MST analysis of RNF146 WWE domain binding to 20-mer PAR, which was 
labeled using ELTA and Cy5-dATP.
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Figure 3. Detection of ADP-ribose length from individual proteins and cells using ELTA.
(a) 15% urea-PAGE analyses of the ELTA labeling reaction of ADP-ribose monomer (lane 
1) and PAR of mixed length (lane 2), as well as ADP-ribose monomers and polymers 
isolated from PARP1 automodification reactions with 1 mM NAD+ for 0 (lane 3), 10 (lane 
4), or 30 min (lane 5) that were labeled by OAS1 and 32P-dATP. As a comparison, the ADP-
ribose isolated from PARP1 automodification reaction in the same time frame with 1 mM 
NAD+ with a trace of 32P-NAD+ were loaded in lanes 6–8. We note that 50-fold less of the 
reaction were loaded in lanes 3–5 compared with lanes 6–8. (b) 15% urea-PAGE analyses of 
ELTA labeling reaction of ADP-ribose monomers and polymers isolated from 
automodification of PARP1 along with either BSA and HPF1. The first lane contained 
ELTA-labeling of an equal mole of 5-, 10- and 20-mer PAR. The reaction in the 
PARP1+BSA lane was diluted 15 times in water prior to ELTA labeling. (c) 15% urea-PAGE 
analyses of the ELTA labeling reaction of ADP-ribose isolated from in vitro modified 
haPARP (lane 1), from untreated HaCaT cells (lane 2), from HaCaT cells treated with 1 mM 
H2O2 for 10 min (lane 3), from HaCaT cells treated with 1 mM H2O2 for 10 min, but pre-
treated the cells with 20 μM PARP inhibitor Olaparib for 2 h (lane 4), or pre-treated with 1 
μM PARG inhibitor PDD00017273 for 2 h (lane 5). Corresponding lysates of cells from 
lanes 2–5 were probed with β-actin.
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Figure 4. Enrichment of ELTA-labeled ADP-ribosylated peptides from complex mixtures.
(a) Schematics of the pipeline to selectively label and enrich ADP-ribosylated peptides. (b) 
MALDI-TOF analyses of (1) the reaction mixtures after ELTA but prior to enrichment, (2) 
the flowthrough from the enrichment matrix, (3) the eluant with the phosphodiesterase 
hsNudT16. The m/z traces shown are the overlay of two experiments, where red lines 
indicate samples with OAS1 and black lines indicate samples without OAS1. (c) The total 
intensity chromatograph (TIC) of the input sample (left), which includes 1 nmol of ADP-
ribosylated peptide HK533 in 1 mg cell lysate peptides, and of the enriched sample after 
elution (middle) and the mass spectrometry scan analyses at the retention time of 6.53 min 
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(right). (d) Quantification of the peptide-spectrum matches (PSM) to the ADP-ribosylated 
peptide HK533 enriched from 1 mg cell lysate peptides, which are dosed with either 1 nmol, 
1 pmol, or 1 fmol HK533. (e) Identified MS/MS spectra of a trypic peptide identified from 
endogenous hnRNPU, with the modification site signified by the addition of a 
phosphoribose group (red).
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Key Resources Table
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-PAR Trevigen Cat#4336-BPC-100
Anti-β-actin(CloneAC15) Millipore Sigma RRID: AB_476692
pan-ADP-ribose binding reagent Millipore Cat#MABE1016; RRID: AB_2665466
IRDye 800CW Streptavidin VWR Cat#RLS000–31
Bacterial and Virus Strains
E. coli BL21 codon plus (DE3)-
RIPL
Agilent Technologies Cat#130280
E. coli RosettaDE3 In-house
Chemicals, Peptides, and 
Recombinant Proteins
α−32P-dATP Perkin Elmer Cat#NEG512H250 UC
Cy3-dATP Perkin Elmer Cat#NEL592001 EA
Cy5-dATP Perkin Elmer Cat#NEL593001EA
N6-(6-amino)hexyl-dATP-Cy5 Jena Bioscience Cat#NU-835-CY5
N6-(6-Azido)hexyl-dATP Jena Bioscience Cat#CLK-NU-002
Biotin-14-dATP ThermoFisher Cat#19524016
DBCO-agarose Click Chemistry Tools Cat#1034
StrepTactin resin IBA Life Sciences Cat#2-1201-025
OAS1 This paper N/A
PARP1 Langelier et al. 2011 N/A
HPF1 Gibbs-Seymour et al. 2016 N/A
PARP10 catalytic domain 
(PARP10CD)
McPherson et al., 2017 N/A
haPARP Slade etal.,2011 N/A
hsNudT16 Daniels et al., 2015 N/A
HK533 Kistemaker et al., 2016 N/A
JV099 Voorneveld et al., 2018 N/A
Activated DNA Trevigen Cat#4671-096-06
Low molecular weight poly(l:C) Invivogen Cat#tlrl-picw
RNaseA ThermoFisher Cat#EN0531
DNasel Roche Cat#10104159001
Proteinase K (as part of High Pure 
miRNA Isolation Kit)
Roche Cat#05080576001
Lysyl Endopeptidase Wako Chemicals Cat#129–02543
Trypsin Protease, MS Grade ThermoFisher Cat#90058
Sigmafast Protease Inhibitor Tablets Millipore Sigma Cat#S8830
TCEP Life Technologies Cat#T2556
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CAM Fisher Scientific Cat#AC14841–0050
2,5-dihydroxybenzoic acid Millipore Sigma Cat#149357
β-Nicotinamide adenine 





SYBR Gold Invitrogen (ThermoFisher) Cat#S11494
Hydrogen peroxide solution (H2O2) Millipore Sigma Cat#H1009
Olaparib Selleckchem Cat#S1060
PDD 00017273 Tocris Cat#5952
Critical Commercial Assays
High Pure miRNA Isolation Kit Roche Cat#05080576001
RiboZol Plus RNA purification kit VWR Cat#97064–954
Pierce™ color silver stain kit ThermoFisher Cat#24597
Deposited Data
Mass Spectrometry data MasslVE MSV000083141
Experimental Models: Cell Lines
HeLa ATCC Cat#CCL-2
Spodoptera frugiperda (SF9) cells ThermoFisher Cat#114496015
BL-21 codon plus (DE3)-RIPL Agilent Technologies Cat#130280





5’ GGGTTGCGGCCGCTTGGG 3’ Langelier et al 2011
3’ CCCAACGCCGGCGAACCC 5’ Langelier et al 2011
Recombinant DNA
pFI Strep Sumo TEV OAS1 This paper N/A





MaxQuant version 1.5.7.4 N/A http://www.coxdocs.org/doku.php?id=maxquant:start
Prism 6 GraphPad https://www.graphpad.com/scientific-software/prism/
MO.Affinity analysis NanoTemper https://nanotempertech.com/monolith/
GeneTools Synoptics https://www.syngene.com/software/genetools-automatic-image-analysis/
ImageStudio 5.2.5 Li-Cor https://www.licor.com/bio/products/software/image_studio/
Other
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Bench protocol This paper Methods S1
Monolith NT.115 Pico NanoTemper https://nanotempertech.com/monolith/
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